To ask the Secretary of State for Health and Social Care, what steps his Department is taking to increase the prescription rates of pancreatic enzyme replacement therapy for inoperable pancreatic cancer patients in England who are not treated in specialist centres.
10 June 2021
Information on the proportion of pancreatic cancer patients in England prescribed with pancreatic enzyme replacement therapy (PERT) is not available in the format requested.
No assessment has been made of rates of prescription of PERT, though we recognise that its use in the treatment of pancreatic cancer can improve patients’ ability recover from treatment and their quality of life. The National Institute of Health and Care Excellence (NICE) clinical guideline on the diagnosis and management of pancreatic cancer describes best practice in the care and treatment of patients with pancreatic cancer, including supporting their nutritional needs. Whilst National Health Service organisations and clinicians should take guidelines and quality standards into account, it is the responsibility of clinicians to make decisions appropriate to the circumstances of each patient.
NHS England and NHS Improvement have commissioned an audit into pancreatic cancer and continue to work with Prostate Cancer UK to raise awareness of PERT, including sharing guidance with Cancer Alliances.